Boston Scientific Corporation (BSX)
Largest Insider Buys in Sector
BSX Stock Price History Chart
BSX Stock Performance
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Activity of Boston Scientific Corporation
Over the last 12 months, insiders at Boston Scientific Corporation have bought $0 and sold $96.9M worth of Boston Scientific Corporation stock.
On average, over the past 5 years, insiders at Boston Scientific Corporation have bought $2.1M and sold $76.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $2.1M was made by WICHMANN DAVID S (director) on 2021‑11‑15.
List of Insider Buy and Sell Transactions, Boston Scientific Corporation
| 2024-11-25 | Sale | EVP& Grp Pres, MedSurg & APAC | 14,010 0.001% | $89.27 | $1.25M | +1.58% | ||
| 2024-11-21 | Sale | director | 4,877 0.0003% | $91.63 | $446,902 | -1.41% | ||
| 2024-11-08 | Sale | EVP, Global Operations | 30,580 0.0021% | $87.66 | $2.68M | +1.98% | ||
| 2024-11-05 | Sale | Chairman, President & CEO | 162,778 0.0111% | $84.75 | $13.79M | +0.25% | ||
| 2024-11-01 | Sale | EVP, Human Resources | 6,983 0.0005% | $84.33 | $588,876 | +6.16% | ||
| 2024-10-07 | Sale | Chairman, President & CEO | 162,777 0.0113% | $84.63 | $13.78M | +3.19% | ||
| 2024-10-07 | Sale | EVP & Group Pres, Cardiology | 132,527 0.0092% | $85.00 | $11.26M | +3.19% | ||
| 2024-10-01 | Sale | EVP, Human Resources | 6,983 0.0005% | $83.86 | $585,594 | +3.39% | ||
| 2024-09-05 | Sale | Chairman, President & CEO | 162,777 0.011% | $81.17 | $13.21M | +5.49% | ||
| 2024-09-03 | Sale | EVP, Human Resources | 6,983 0.0005% | $81.70 | $570,511 | +4.41% | ||
| 2024-08-28 | Sale | EVP & Group Pres, Cardiology | 14,132 0.001% | $80.00 | $1.13M | +6.33% | ||
| 2024-08-26 | Sale | EVP& Grp Pres, MedSurg & APAC | 14,012 0.0009% | $79.25 | $1.11M | +6.35% | ||
| 2024-08-01 | Sale | EVP, Human Resources | 6,983 0.0005% | $74.12 | $517,580 | +11.66% | ||
| 2024-07-01 | Sale | EVP, Human Resources | 6,983 0.0005% | $77.30 | $539,786 | 0.00% | ||
| 2024-06-03 | Sale | EVP, Human Resources | 6,983 0.0005% | $75.33 | $526,029 | +8.90% | ||
| 2024-05-29 | Sale | EVP&Pres, Periph Intervent | 63,802 0.0043% | $75.10 | $4.79M | +9.08% | ||
| 2024-05-28 | Sale | EVP& Grp Pres, MedSurg & APAC | 14,011 0.001% | $75.34 | $1.06M | +8.67% | ||
| 2024-05-23 | Sale | EVP and CFO | 47,621 0.0033% | $75.11 | $3.58M | +9.55% | ||
| 2024-05-22 | Sale | EVP and CFO | 64,454 0.0044% | $75.91 | $4.89M | +7.96% | ||
| 2024-05-22 | Sale | SVP, GC and Corp. Secretary | 15,006 0.001% | $76.01 | $1.14M | +7.96% |
Insider Historical Profitability
| Mahoney Michael F | Chairman, President & CEO | 1521205 0.1032% | $90.66 | 2 | 25 | +37.05% |
| Brennan Daniel J. | EVP and CFO | 223921 0.0152% | $90.66 | 0 | 23 | |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 160467 0.0109% | $90.66 | 0 | 19 | |
| LUDWIG EDWARD J | director | 39398 0.0027% | $90.66 | 1 | 3 | +26.95% |
| Sorenson John Bradley | EVP, Global Operations | 39706 0.0027% | $90.66 | 0 | 27 | |
| Carruthers Wendy | EVP, Human Resources | 32028 0.0022% | $90.66 | 0 | 45 | |
| Brown Vance R | SVP, GC and Corp. Secretary | 32326 0.0022% | $90.66 | 0 | 3 | |
| Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 31422 0.0021% | $90.66 | 0 | 13 | |
| Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 28022 0.0019% | $90.66 | 0 | 43 | |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 978 0.0001% | $90.66 | 0 | 18 | |
| Dockendorff Charles J | director | 0 0% | $90.66 | 1 | 2 | +35.4% |
| NICHOLAS PETER M | director | 3531021 0.2396% | $90.66 | 0 | 249 | |
| ABELE JOHN E | Director Emeritus | 500000 0.0339% | $90.66 | 5 | 212 | +7.41% |
| Bose Supratim | EVP & President, Asia-Pacific | 320301 0.0217% | $90.66 | 0 | 2 | |
| BEST LAWRENCE C | EVP | 232189 0.0158% | $90.66 | 1 | 24 | <0.0001% |
| NICHOLAS NJ JR | director | 225000 0.0153% | $90.66 | 20 | 1 | +2.99% |
| Nanavaty Maulik | SVP & Pres, Neuromodulation | 166869 0.0113% | $90.66 | 0 | 22 | |
| Pratt Timothy A. | EVP, GC & Chief Admin Officer | 154681 0.0105% | $90.66 | 0 | 32 | |
| ELLIOTT JOHN RAYMOND | director | 118264 0.008% | $90.66 | 1 | 0 | <0.0001% |
| Kucheman William | Chief Executive Officer | 112525 0.0076% | $90.66 | 3 | 1 | +27.04% |
| Lance Jean Fitterer | SVP, Asst GC, Bus & Regions | 97504 0.0066% | $90.66 | 0 | 10 | |
| Phalen Michael P. | EVP & President, MedSurg | 97910 0.0066% | $90.66 | 0 | 38 | |
| MARIO ERNEST | director | 86032 0.0058% | $90.66 | 22 | 18 | +4.5% |
| Ballinger Kevin J. | EVP & Pres, Interven Cardio | 80085 0.0054% | $90.66 | 0 | 25 | |
| Wang Xin Warren | SVP and Pres, Asia Pacific | 75469 0.0051% | $90.66 | 0 | 4 | |
| Dawkins Keith D | EVP, Global Chief Med. Off. | 68165 0.0046% | $90.66 | 0 | 4 | |
| PEPPER JOHN E | director | 58807 0.004% | $90.66 | 3 | 0 | <0.0001% |
| Pucel Kenneth | EVP, Glob Ops, Qual & Tech | 59000 0.004% | $90.66 | 0 | 1 | |
| TOBIN JAMES R | President and CEO | 50000 0.0034% | $90.66 | 0 | 2 | |
| LAVIOLETTE PAUL A | COO | 49422 0.0034% | $90.66 | 0 | 5 | |
| MCCONNELL WILLIAM F JR | SVP, Administration CRM | 48949 0.0033% | $90.66 | 0 | 2 | |
| Prange Karen | SVP&Pres, Uro & Pelvic Health | 38395 0.0026% | $90.66 | 0 | 6 | |
| MACLEAN ROBERT G | SVP, HR | 36502 0.0025% | $90.66 | 0 | 10 | |
| Monson Jonathan | SVP, Global Controller and CAO | 34868 0.0024% | $90.66 | 0 | 5 | |
| SANDMAN PAUL W | EVP and General Counsel | 33866 0.0023% | $90.66 | 0 | 4 | |
| Sununu John E | director | 32265 0.0022% | $90.66 | 3 | 4 | +4.31% |
| Bartlett Katharine T | director | 29708 0.002% | $90.66 | 1 | 0 | +4.24% |
| Meredith Ian T | EVP Global Chief Med Officer | 28082 0.0019% | $90.66 | 0 | 2 | |
| Connors Nelda J | director | 27246 0.0018% | $90.66 | 1 | 4 | <0.0001% |
| WICHMANN DAVID S | director | 25000 0.0017% | $90.66 | 1 | 0 | +0.3% |
| Mackey Edward F | EVP, Operations | 23722 0.0016% | $90.66 | 0 | 3 | |
| Eddy Jodi Euerle | SVP, Chief Info & Digital Off. | 23263 0.0016% | $90.66 | 0 | 8 | |
| Scanlon Meghan | SVP,Pres,Urology Pelvic Health | 19142 0.0013% | $90.66 | 0 | 2 | |
| FLEISHMAN JOEL LAWRENCE | director | 18250 0.0012% | $90.66 | 1 | 0 | +1.14% |
| Olson Scott | SVP & Pres, CRM, Diagnostics | 14518 0.001% | $90.66 | 0 | 6 | |
| BURNS URSULA M | director | 13500 0.0009% | $90.66 | 4 | 0 | <0.0001% |
| Ralls-Morrison Desiree | SVP, GC and Corp Secretary | 11450 0.0008% | $90.66 | 0 | 3 | |
| TAYLOR JAMES H JR | Sr. VP, Operations | 9360 0.0006% | $90.66 | 0 | 4 | |
| MORECI STEPHEN F | SVP, Global Sales Operations | 7216 0.0005% | $90.66 | 1 | 7 | <0.0001% |
| REINHARDT UWE E | director | 5000 0.0003% | $90.66 | 3 | 1 | <0.0001% |
| Goodman Jeffrey H | SVP, International | 5000 0.0003% | $90.66 | 2 | 0 | <0.0001% |
| FOX MARYE ANNE | director | 3305 0.0002% | $90.66 | 1 | 0 | +18.63% |
| GROVES RAY J | director | 1000 0.0001% | $90.66 | 3 | 0 | <0.0001% |
| BARTELL MARK C | SVP Global Sales/Mkt CRM | 1812 0.0001% | $90.66 | 0 | 1 | |
| Burns Brian R | EVP - Global Quality & Reg Aff | 1289 0.0001% | $90.66 | 0 | 1 | |
| JOHNSON KRISTINA M | director | 0 0% | $90.66 | 0 | 3 | |
| DEPARLE NANCY ANN | director | 0 0% | $90.66 | 0 | 2 | |
| COLEN FRED | EVP & Chief Technology Officer | 0 0% | $90.66 | 0 | 18 | |
| CAPELLO JEFFREY D | EVP & Chief Financial Officer | 447 0% | $90.66 | 0 | 5 | |
| FUJIMORI YOSHIAKI | director | 0 0% | $90.66 | 0 | 1 | |
| Russell Mary E | SVP and CMO | 0 0% | $90.66 | 0 | 2 | |
| Pedersen John B. | Pres, Uro & Women's Health | 0 0% | $90.66 | 0 | 3 | |
| Pierce David A | EVP Pres MedSurg | 0 0% | $90.66 | 0 | 88 |
Institutional Investor Ownership
| Fidelity Investments | $9.72B | 9.65 | 141.93M | +2.66% | +$251.98M | 0.65 | |
| The Vanguard Group | $8.73B | 8.67 | 127.44M | +1.58% | +$136.16M | 0.16 | |
| BlackRock | $8.69B | 8.63 | 126.84M | +0.22% | +$18.9M | 0.19 | |
| State Street | $4.3B | 4.27 | 62.73M | +0.63% | +$26.96M | 0.18 | |
| Massachusetts Financial Services Co Ma | $3.19B | 3.17 | 46.61M | -18.48% | -$723.87M | 0.95 | |
| PRIMECAP Management Co | $2.6B | 2.58 | 37.95M | +0.11% | +$2.88M | 1.91 | |
| Wellington Management Company | $2.28B | 2.26 | 33.29M | -8.65% | -$215.9M | 0.39 | |
| JPMorgan Chase | $2.16B | 2.14 | 31.48M | +9.94% | +$194.92M | 0.19 | |
| Bank of America | $2.05B | 2.04 | 29.96M | +6.45% | +$124.28M | 0.2 | |
| Geode Capital Management | $1.94B | 1.94 | 28.45M | +3.25% | +$61.22M | 0.17 | |
| The Bollard Group | $1.51B | 1.5 | 22M | -1.75% | -$26.91M | 45.74 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.41B | 1.4 | 20.62M | -2.41% | -$34.83M | 1.52 | |
| Janus Henderson | $1.27B | 1.27 | 18.61M | -4.31% | -$57.42M | 0.64 | |
| Morgan Stanley | $1.23B | 1.22 | 17.96M | -4.25% | -$54.57M | 0.09 | |
| Artisan Partners | $1.11B | 1.1 | 16.18M | -5.78% | -$67.97M | 1.63 | |
| Capital World Investors | $1.1B | 1.09 | 16.01M | +69.94% | +$451.23M | 0.18 | |
| Franklin Templeton Investments | $1.07B | 1.07 | 15.68M | +929.91% | +$969.43M | 0.32 | |
| BNY Mellon | $1.06B | 1.05 | 15.47M | -8.82% | -$102.54M | 0.2 | |
| Goldman Sachs | $1B | 1 | 14.67M | -8.49% | -$93.15M | 0.19 | |
| Legal & General | $928.86M | 0.92 | 13.56M | +0.28% | +$2.59M | 0.22 | |
| Northern Trust | $894.41M | 0.89 | 13.06M | -4.97% | -$46.78M | 0.15 | |
| Invesco | $863.06M | 0.86 | 12.6M | +0.43% | +$3.66M | 0.18 | |
| Nuveen | $818.93M | 0.81 | 11.96M | +15.53% | +$110.1M | 0.23 | |
| Amundi | $747.36M | 0.75 | 11.09M | -19.06% | -$176M | 0.31 | |
| Vontobel Asset Management Inc | $728.45M | 0.68 | 9.98M | -9.04% | -$72.36M | 4.04 | |
| Millennium Management LLC | $615.02M | 0.65 | 9.48M | +28.66% | +$136.98M | 0.4 | |
| Citadel Advisors LLC | $600.94M | 0.6 | 8.77M | -2.31% | -$14.21M | 0.34 | |
| Voya Investment Management LLC | $575.02M | 0.57 | 8.4M | +20.96% | +$99.64M | 0.62 | |
| Charles Schwab | $540.55M | 0.54 | 7.89M | +2.57% | +$13.54M | 0.12 | |
| Canada Pension Plan Investment Board | $540.88M | 0.54 | 7.9M | +14.96% | +$70.38M | 0.55 | |
| UBS | $532.74M | 0.53 | 7.78M | +10.31% | +$49.77M | 0.16 | |
| LAZARD ASSET MANAGEMENT LLC | $508.87M | 0.51 | 7.43M | -15.84% | -$95.78M | 0.67 | |
| Ubs Asset Management Americas Inc | $501.58M | 0.5 | 7.32M | -7.82% | -$42.56M | 0.18 | |
| T. Rowe Price | $491.91M | 0.49 | 7.18M | +13.94% | +$60.16M | 0.06 | |
| Ameriprise Financial | $416.08M | 0.41 | 6.08M | -19.26% | -$99.27M | 0.12 | |
| Holocene Advisors, LP | $396.42M | 0.39 | 5.79M | -26.6% | -$143.63M | 1.47 | |
| Fil Ltd | $384.17M | 0.38 | 5.61M | -5.65% | -$22.99M | 0.38 | |
| Bank of Montreal | $355.29M | 0.35 | 5.17M | -1.46% | -$5.25M | 0.11 | |
| Arrowstreet Capital, Limited Partnership | $335.73M | 0.33 | 4.9M | -18.95% | -$78.49M | 0.31 | |
| Agf Management Ltd | $332.48M | 0.33 | 4.85M | -0.09% | -$304,164.09 | 1.87 | |
| Winslow Capital Management Llc | $331.92M | 0.33 | 4.85M | -3.73% | -$12.86M | 1.25 | |
| Dimensional Fund Advisors | $317.52M | 0.32 | 4.64M | +2.36% | +$7.33M | 0.08 | |
| Farallon Capital | $314.83M | 0.31 | 4.6M | -21.02% | -$83.8M | 2.21 | |
| SEI Investments Company | $313.2M | 0.31 | 4.57M | -0.07% | -$211,839.45 | 0.47 | |
| Impax Asset Management Group | $305.1M | 0.3 | 4.47M | +2.83% | +$8.41M | 1.17 | |
| Investec Asset Management UK | $301.29M | 0.3 | 4.4M | -1.12% | -$3.4M | 0.85 | |
| Swiss National Bank | $300.48M | 0.3 | 4.39M | -4.18% | -$13.12M | 0.2 | |
| Deutsche Bank | $298.51M | 0.3 | 4.36M | +7.45% | +$20.7M | 0.14 | |
| Royal Bank of Canada | $295.4M | 0.29 | 4.31M | -1.28% | -$3.82M | 0.07 | |
| Barclays | $277.15M | 0.28 | 4.05M | +19.91% | +$46.01M | 0.13 |